(Q34879435)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23896722%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

meta-analysis

0 references

title

Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23896722%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

0 references

0 references

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23896722%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

author name string

Taro Kishi

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23896722%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Tomohiko Mukai

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23896722%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Yuki Matsuda

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23896722%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

publication date

30 July 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23896722%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

published in

NeuroMolecular Medicine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23896722%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23896722%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23896722%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

page(s)

61-69

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23896722%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12017-013-8251-0

6 March 2020

exact match

0 references

cites work

Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8251-0

The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8251-0

Manual for the Extrapyramidal Symptom Rating Scale (ESRS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8251-0

Management of treatment resistance in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8251-0

Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8251-0

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8251-0

Interactions between 5-HT3 receptors and cerebral dopamine function: implications for the treatment of schizophrenia and psychoactive substance abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8251-0

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8251-0

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8251-0

Toward a structural basis for the function of nicotinic acetylcholine receptors and their cousins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8251-0

Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8251-0

Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8251-0

Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8251-0

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8251-0

A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8251-0

Treatment-resistant schizophrenia--the role of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8251-0

Serotonergic mechanisms as targets for existing and novel antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8251-0

Update on typical and atypical antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8251-0

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8251-0

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8251-0

A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8251-0

A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8251-0

Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8251-0

Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8251-0

Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-013-8251-0

How meta-analysis increases statistical power

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23896722

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23896722

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23896722